Esperion Therapeutics Inc. (ESPR) announced after the bell Tuesday that they have failed to reach an agreement with the FDA on a regulatory pathway for an LDL-C lowering indication in the U.S. on ETC-1002 in statin intolerant patients.
from RTT - Before the Bell http://ift.tt/29sJ9At
via IFTTT
No comments:
Post a Comment